Physician profile
Rezaul Islam
NPI 1841237286
$8,131.45
in general payments reported to CMS, 2019-2025
31 companies · $804 in 2025
The $804 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,094 · 2020: $1,976 · 2021: $775 · 2022: $459 · 2023: $2,409 · 2024: $616 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,936 · Travel and Lodging: $892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.39 |
| Travel and Lodging | $891.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,651.99 | 2021-2025 | Turbohawk, In.Pact Admiral, Hawkone |
| Medtronic Vascular, INC. | $1,324.30 | 2020 | |
| Abbott Laboratories | $895.70 | 2019-2025 | Assurity, Merlin@Home |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $797.87 | 2019-2025 | Lifevest |
| Cardiovascular Systems INC. | $635.77 | 2019-2023 | Diamondback Peripheral |
| Novartis Pharmaceuticals Corporation | $433.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $254.75 | 2021-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $167.69 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $116.10 | 2023-2024 | Inpefa |
| Amgen INC. | $107.82 | 2019-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $87.95 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.13 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $73.55 | 2019-2024 | Xarelto |
| Pfizer INC. | $69.53 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $68.97 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $64.55 | 2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $36.37 | 2019-2021 | |
| Boston Scientific Corporation | $34.36 | 2024-2025 | Watchman Access System |
| Terumo Medical Corporation | $32.02 | 2019-2020 | |
| Siemens Medical Solutions USA, INC. | $24.63 | 2020 | |
| Genzyme Corporation | $23.10 | 2019 | |
| Novo Nordisk INC | $22.97 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $21.21 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $17.36 | 2024 | Opsumit |
| Scpharmaceuticals INC. | $14.46 | 2025 | |
| Penumbra, INC. | $14.22 | 2024 | Indigo System |
| Sanofi-Aventis U.S. LLC | $14.20 | 2023 | |
| Tactile Systems Technology INC | $13.68 | 2019 | |
| Amarin Pharma, INC. | $13.64 | 2020 | |
| Bardy Diagnostics, INC. | $13.28 | 2019 | |
| Irhythm Technologies, INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rezaul Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.